Houston, Texas, U.S. | April 15, 2026

Eli Lilly and Company has announced a strategic agreement to acquire CrossBridge Bio, Inc., a pre-clinical biotechnology company focused on next-generation dual-payload antibody-drug conjugates (ADCs), in a deal valued at up to $300 million in total consideration. This acquisition strengthens Lilly’s oncology pipeline by integrating an innovative dual-payload ADC platform designed to enhance therapeutic efficacy and overcome resistance mechanisms in cancer treatment. The move reflects Lilly’s continued commitment to advancing cutting-edge oncology therapeutics and expanding its portfolio of targeted cancer therapies aimed at improving patient outcomes.

Strategic Acquisition Expands ADC Innovation in Oncology

The acquisition of CrossBridge Bio provides Eli Lilly with access to a novel dual-payload ADC technology platform, originally developed at the University of Texas Health Science Center at Houston (UTHealth Houston). This platform is designed to deliver two complementary therapeutic payloads within a single antibody construct, enabling a synergistic approach to tumor targeting and cell killing.

By combining different mechanisms of action, dual-payload ADCs aim to increase tumor response rates, enhance durability of treatment effects, and address resistance pathways that often limit the effectiveness of traditional single-payload ADCs. This strategic move positions Lilly at the forefront of next-generation ADC development, an area of significant growth in oncology drug innovation.

Lead Asset CBB-120 Targets TROP2 in Solid Tumors

Advertisement

cGxPJobs Banner

At the core of the acquisition is CBB-120, a TROP2-targeting dual-payload ADC, which combines a topoisomerase I inhibitor (TOP1i) and an ATR inhibitor (ATRi) within a single therapeutic construct. TROP2 is a well-established target in multiple solid tumors, including breast, lung, and colorectal cancers, making it a critical focus for targeted therapy development. CBB-120 is designed to enhance the therapeutic index by maximizing tumor cell killing while minimizing off-target toxicity, and to overcome resistance mechanisms commonly observed with existing ADC therapies. The program is currently in preclinical development, with a U.S. FDA Investigational New Drug (IND) application anticipated in 2026, marking its transition toward clinical evaluation.

Accelerating Clinical Development Through Strategic Integration

By integrating CrossBridge Bio’s technology into its R&D infrastructure, Eli Lilly aims to accelerate the development and clinical translation of dual-payload ADCs, leveraging its global capabilities in drug development, regulatory strategy, and commercialization. The acquisition also reflects a broader industry trend toward platform-based innovation, where pharmaceutical companies acquire emerging technologies to enhance pipeline productivity and address unmet medical needs. CrossBridge Bio’s rapid progress since its founding in 2023 highlights the value of early-stage biotech innovation in driving transformative therapies, particularly in oncology.

Financial and Strategic Implications of the Deal

Under the terms of the agreement, CrossBridge Bio shareholders may receive up to $300 million, including upfront and milestone-based payments, aligning incentives with the successful development of the platform. The transaction underscores the growing importance of mergers and acquisitions (M&A) in the biopharma sector, as companies seek to strengthen their competitive position through strategic investments in innovative technologies. The involvement of leading investors and research institutions further validates the scientific potential of CrossBridge Bio’s platform and its relevance in the evolving oncology landscape.

Advancing the Future of Targeted Cancer Therapies

The acquisition represents a significant step forward in the evolution of antibody-drug conjugate technology, which continues to gain traction as a powerful modality in cancer treatment. By advancing dual-payload ADCs, Eli Lilly is contributing to the development of more effective and durable cancer therapies, addressing critical challenges such as tumor heterogeneity and drug resistance. This approach aligns with the broader shift toward precision oncology, where therapies are designed to target specific molecular pathways and deliver enhanced clinical outcomes.

Eli Lilly’s acquisition of CrossBridge Bio marks a pivotal milestone in the advancement of next-generation ADC technologies, reinforcing the company’s leadership in oncology innovation. With a promising pipeline led by CBB-120 and a novel dual-payload platform, the deal has the potential to reshape treatment paradigms in cancer care. As development progresses, this collaboration is expected to drive clinical breakthroughs, regulatory advancements, and improved patient outcomes, highlighting the critical role of strategic acquisitions in accelerating pharmaceutical innovation.

Source: Eli Lilly, CrossBridge Bio press release